You are here

FDA Staff Question Efficacy of Tobramycin Inhaled Powder for Cystic Fibrosis

Approval decision scheduled for September 5 (Aug. 31)

According to an August 31 report from Reuters, FDA reviewers have questioned whether tobramycin inhaled powder, from Novartis, truly improves breathing in cystic fibrosis patients. Only one of two clinical trials showed that the tobramycin powder worked better than placebo.

The FDA staff released their opinion ahead of the agency’s approval meeting, which is scheduled for Wednesday, September 5.

Novartis is seeking an indication for the inhaled powder as a more convenient alternative to the nebulized solution (TOBI).

Tobramycin is an aminoglycoside antibiotic.

For more information, visit the Reuters Web site.

Recent Headlines

Superior to Quinine in Reducing Mortality in Two Clinical Trials
Minimally Invasive Method Reduces Regurgitation and Leaking
Neurofilament Light Protein Correlated With Accumulated Brain Damage
Technology Designed to Improve Patient Care, Limit Infections
Medical Device Enables Nerve Stimulation During Sleep
May Offer Improved Safety Profile for Pediatric Patients
Hope for Sufferers With Post-Treatment Lyme Disease Syndrome
KardiaMobile Receives Two More Clearances for Arrhythmia Detection
Possible First Treatment Option for Rare Autoimmune Disease of the CNS